Scientists at McMaster University have discovered several new biomarkers from a single drop of blood that could allow earlier and more definitive detection of cystic fibrosis (CF), a genetic disease which strikes both children and adults, causing chronic problems with the digestive system and the lungs.
The findings, published online in the Journal of Proteome Research, are significant because current newborn screening methods are not accurate enough to identify the disorder in the population, which can manifest itself in many different ways, requiring additional testing and causing further stress for anxious parents.
“The earlier CF is detected, the earlier it can be managed and treated, which means better health outcomes for affected infants, including their future growth and development,” says Philip Britz-McKibbin, lead author of the study and a professor in McMaster’s Department of Chemistry & Chemical Biology, who conducted the research with graduate student Alicia DiBattista, now a postdoctoral fellow at Newborn Screening Ontario (NSO).
A tiny amount of blood is drawn from the heel of all babies as part of universal newborn screening programs that test for many rare yet treatable diseases since babies usually have no signs of disease at birth, including CF.
In the case of CF, infants are screened for a pancreatic enzyme and then a panel of disease-causing genetic mutations associated with CF. However, further testing to confirm or rule out the disease finds that most babies who screen-positive do not actually have the disease. These babies are later found to be “healthy carriers” or their results are deemed to be “false positives”.
With this in mind, researchers set out to determine whether they could discover chemical signatures in a dried blood spot that could better distinguish infants who have CF from those who do not.
Using less than a single drop of blood stored at NSO at CHEO, a pediatric health and research centre in Ottawa, researchers analyzed and compared samples from infants confirmed to have CF with the samples of both healthy and screen positive infants. They found several new compounds as well as simple amino acids directly related to affected infants with CF who otherwise have no symptoms and normal birth weight.
“These biomarkers provide new insights into the disease process early in life before symptoms are fully apparent,” says Britz-McKibbin. “Moreover, these compounds can be analyzed by mass spectrometry at incremental costs since it is already used for testing many other genetic diseases at newborn screening facilities around the world”
“Ontario started screening for Cystic Fibrosis in April 2007, and since that time over 400 children have already benefited from early recognition and early treatment. But for every one of these children, about 10 have had a false-positive result. We want to get this number down and are very hopeful that the new biomarkers discovered by this research project will help us do exactly that,” says Pranesh Chakraborty, medical director of NSO at CHEO.
In Canada, life expectancy rates have risen dramatically with the median age of survival now over 50 years, due to better treatments to improve lung function, better nutrition, lung transplants. The advent of universal newborn screening programs for CF will likely further improve the quality of life of affected patients.
“We know that early detection can have significant benefits for people living with cystic fibrosis,” said Dr. John Wallenburg, chief scientific officer at Cystic Fibrosis Canada. “The current screening methodologies capture a broad swathe of families that then need further testing to narrow down those that are true positives. The anxiety and distress that such further testing can needlessly cause families was a major concern that slowed the adoption of newborn screening in some jurisdictions. Dr. Britz-McKibbin’s data provide insights for more specific newborn screening, as well as early manifestations of the disease.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Bid for Bachelors & Bachelorettes fundraiser to help those with Cystic Fibrosison February 27, 2020 at 8:42 am
GRAND RAPIDS, Mich. (WOOD) – The 23rd Annual Bid for Bachelors and Bachelorettes is an auction style fundraiser supporting Friends & Families of Cystic Fibrosis – an all volunteer nonprofit ...
- Cystic Fibrosis Treatment Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2026on February 27, 2020 at 5:23 am
A recent report provides crucial insights along with application based and forecast information in the Global Cystic Fibrosis Treatment Market. The report provides a comprehensive analysis of key ...
- BRAUN: People die while Ontario stalls on cystic fibrosis drugson February 26, 2020 at 6:36 pm
Christine Elliott has a secret talent: tap dancing! Ontario’s Minister of Health put on an impressive display of bobbing, weaving, sidestepping and waffling at Queen’s Park on Wednesday, all to dance ...
- Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resourceson February 26, 2020 at 4:27 pm
Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by ...
- BRIEF-Eloxx Strengthens Its Commitment To Cystic Fibrosis Through Reallocating Resourceson February 26, 2020 at 4:06 pm
* ELOXX PHARMACEUTICALS - EXPECTS TO REPORT TOPLINE DATA FROM ITS PHASE 2 CYSTIC FIBROSIS CLINICAL TRIAL PROGRAM FOR ELX-02 DURING FIRST HALF OF 2020 Source text for Eikon: Further company coverage: ...
- Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealandon February 26, 2020 at 4:52 am
today announced that KALYDECO® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1. Clinicians are able to apply for patient access using the excep ...
- Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosison February 26, 2020 at 4:30 am
portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) ...
- Cystic fibrosis is the reason for denial of teen's re-entry visa by Australian Government, family sayson February 25, 2020 at 9:30 pm
A young Irish man with cystic fibrosis who calls Western Australia home has been denied entry back into the country because the cost of his medication is too high, his family has said. Sean Colgan's ...
- Global Cystic Fibrosis Therapeutics Market (2019 to 2026) - CAGR of 9.2% Expected During the Forecast Period - ResearchAndMarkets.comon February 24, 2020 at 6:49 am
DUBLIN--(BUSINESS WIRE)--The "Cystic Fibrosis Therapeutics Market by Drug Class and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ...
- AZ Business Group Honored At Cystic Fibrosis Foundation Eventon February 21, 2020 at 2:39 pm
The award is given to a corporate supporter who has increased or expanded participation and fundraising efforts for Great Strides. TEMPE, AZ – The Arizona Business Group, a collective of CARSTAR ...
via Bing News